MA29389B1 - Hydroxamates utilises en tant qu'inhibiteurs de desacetylase d'histones et formulations pharmaceutiques les contenant. - Google Patents

Hydroxamates utilises en tant qu'inhibiteurs de desacetylase d'histones et formulations pharmaceutiques les contenant.

Info

Publication number
MA29389B1
MA29389B1 MA30291A MA30291A MA29389B1 MA 29389 B1 MA29389 B1 MA 29389B1 MA 30291 A MA30291 A MA 30291A MA 30291 A MA30291 A MA 30291A MA 29389 B1 MA29389 B1 MA 29389B1
Authority
MA
Morocco
Prior art keywords
histonic
hydroxamates
pharmaceutical formulations
formulations containing
containing same
Prior art date
Application number
MA30291A
Other languages
English (en)
Inventor
Cristina Rossi
Marina Porcelloni
Andrea Piero D
Daniela Fattori
Elena Marastoni
Original Assignee
Menarini Int Operations Lu Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Menarini Int Operations Lu Sa filed Critical Menarini Int Operations Lu Sa
Publication of MA29389B1 publication Critical patent/MA29389B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/11—Compounds covalently bound to a solid support

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'INVENTION CONCERNE DES COMPOSÉS AYANT LA STRUCTURE (I) AYANT UNE ACTIVITÉ D'INHIBITEURS D'HYSTONE DÉSACÉTYLASE (HDAC). LES COMPOSÉS SONT CARACTÉRISÉS CHIMIQUEMENT PAR LA PRÉSENCE D'ACIDE HYDROXAMIQUE, LE ZINC ÉTANT UTILISÉ COMME CHÉLATEUR, ET PAR UN NOYAU AROMATIQUE CONNECTÉ PAR UN LIEUR DANS LEQUEL EST PRÉSENT SOIT UN SYSTÈME AROMATIQUE BICYCLIQUE SOIT UN ANNEAU PIPÉRIDINO.
MA30291A 2005-03-15 2007-10-11 Hydroxamates utilises en tant qu'inhibiteurs de desacetylase d'histones et formulations pharmaceutiques les contenant. MA29389B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000041A ITFI20050041A1 (it) 2005-03-15 2005-03-15 Idrossammati come inibitori dell'istone deacelitasi, loro preparazione e formulazioni farmaceutiche che li contengono
IT000239A ITFI20050239A1 (it) 2005-03-15 2005-11-21 Idrossammati come inibitori dell'istone deacetilasi e formulazioni farmaceutiche che li contegono

Publications (1)

Publication Number Publication Date
MA29389B1 true MA29389B1 (fr) 2008-04-01

Family

ID=36617217

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30291A MA29389B1 (fr) 2005-03-15 2007-10-11 Hydroxamates utilises en tant qu'inhibiteurs de desacetylase d'histones et formulations pharmaceutiques les contenant.

Country Status (22)

Country Link
US (1) US20080207694A1 (fr)
EP (1) EP1868997A1 (fr)
JP (1) JP2008533091A (fr)
KR (1) KR20070112240A (fr)
CN (1) CN101155780A (fr)
AP (1) AP2007004188A0 (fr)
AR (1) AR058002A1 (fr)
AU (1) AU2006224624A1 (fr)
BR (1) BRPI0606290A2 (fr)
CA (1) CA2600528A1 (fr)
CO (1) CO6321134A2 (fr)
CR (1) CR9431A (fr)
EA (1) EA012909B1 (fr)
IL (1) IL185882A0 (fr)
IT (2) ITFI20050041A1 (fr)
MA (1) MA29389B1 (fr)
MX (1) MX2007011072A (fr)
NO (1) NO20075281L (fr)
SA (1) SA06270135B1 (fr)
TW (1) TW200724529A (fr)
WO (1) WO2006097460A1 (fr)
ZA (1) ZA200708749B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080255149A1 (en) * 2005-09-27 2008-10-16 Novartis Ag Carboxyamine Compounds and Methods of Use Thereof
GB0523040D0 (en) * 2005-11-11 2005-12-21 Cyclacel Ltd Combination
JP2010536876A (ja) * 2007-08-21 2010-12-02 アークル インコーポレイテッド Ｈｄａｃインヒビター
CN102775368B (zh) 2011-05-10 2016-08-17 上海驺虞医药科技有限公司 一类噻唑类化合物及其制备方法和用途
US10654814B2 (en) * 2015-12-22 2020-05-19 Kancera Ab Bicyclic hydroxamic acids useful as inhibitors of mammalian histone deacetylase activity
EP3398598B1 (fr) * 2015-12-31 2022-04-06 Hitgen Inc. Dérivé du sulfonamide, son procédé de préparation et son procédé d'utilisation
CN112041307B (zh) 2018-02-06 2024-02-09 伊利诺伊大学评议会 作为选择性雌激素受体降解剂的取代的苯并噻吩类似物
CN112325620B (zh) * 2020-11-13 2022-04-19 南阳中联水泥有限公司 一种水泥生产高效烘干设备
CN112516142B (zh) * 2020-12-11 2021-10-15 北京华氏精恒医药科技有限公司 一种具有hdac抑制活性的药物组合物、制备方法及其用途
WO2023003468A1 (fr) * 2021-07-23 2023-01-26 Rijksuniversiteit Groningen Nouveaux inhibiteurs de l'histone désacétylase (hdac), procédés, compositions et utilisations s'y rapportant
WO2025041160A1 (fr) * 2023-08-19 2025-02-27 Birla Institute Of Technology And Science (Bits), Pilani Molécules conjuguées bifonctionnelles pour le traitement du cancer et leur procédé de fabrication

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2475766C (fr) * 2002-03-13 2012-06-05 Janssen Pharmaceutica N.V. Derives piperazinyl-, piperidinyl- et morpholinyl- utilises en tant que nouveaux inhibiteurs d'histone deacetylase
NZ536116A (en) * 2002-04-03 2007-01-26 Topotarget Uk Ltd Carbamic acid compounds comprising a piperazine linkage as HDAC inhibitors
US20040072802A1 (en) * 2002-10-09 2004-04-15 Jingwu Duan Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha
EP1663201A4 (fr) * 2003-07-15 2009-10-28 Korea Res Inst Of Bioscience Utilisation des nouveaux composes 2-oxo-heterocycliques et des compositions pharmaceutiques les contenant
TW200530166A (en) * 2003-10-27 2005-09-16 S Bio Pte Ltd Acylurea connected and sulfonylurea connected hydroxamates

Also Published As

Publication number Publication date
AU2006224624A1 (en) 2006-09-21
EP1868997A1 (fr) 2007-12-26
AP2007004188A0 (en) 2007-10-31
WO2006097460A8 (fr) 2007-11-01
US20080207694A1 (en) 2008-08-28
TW200724529A (en) 2007-07-01
IL185882A0 (en) 2008-01-06
ZA200708749B (en) 2009-08-26
KR20070112240A (ko) 2007-11-22
CR9431A (es) 2008-07-31
CO6321134A2 (es) 2011-09-20
EA200701970A1 (ru) 2008-02-28
JP2008533091A (ja) 2008-08-21
CN101155780A (zh) 2008-04-02
ITFI20050041A1 (it) 2006-09-16
SA06270135B1 (ar) 2009-07-19
BRPI0606290A2 (pt) 2009-06-09
CA2600528A1 (fr) 2006-09-21
ITFI20050239A1 (it) 2007-05-22
MX2007011072A (es) 2007-10-08
WO2006097460A1 (fr) 2006-09-21
AR058002A1 (es) 2008-01-23
NO20075281L (no) 2007-10-15
EA012909B1 (ru) 2010-02-26

Similar Documents

Publication Publication Date Title
MA29389B1 (fr) Hydroxamates utilises en tant qu'inhibiteurs de desacetylase d'histones et formulations pharmaceutiques les contenant.
EA200401202A1 (ru) Сульфонилпроизводные в качестве новых ингибиторов гистон-деацетилазы
MA31183B1 (fr) Inhibiteurs de mek
EA200401197A1 (ru) Пиперазинил-, пиперидинил- и морфолинилпроизводные как новые ингибиторы гистондеацетилазы
EP1302542A4 (fr) Nouveau peptide actif sur le plan physiologique et utilisation associee
DE60232797D1 (de) Histon deazetylase enzym-hemmende hydroxamsäurederivate als neue entzündungshemmer zur hemmung der zytokinsynthese
EA200100905A1 (ru) Фармацевтическая композиция, содержащая ингибиторы протонного насоса
Deprez-Poulain et al. Structure–activity relationships and blood distribution of antiplasmodial aminopeptidase-1 inhibitors
EA199900768A1 (ru) N-гидрокси-2- (алкил, арил или гетероарилсульфанил, сульфинил или сульфонил) -3-замещенный алкил, арил или гетероариламиды в качестве ингибиторов матричной металлопротеиназы
EA200401201A1 (ru) Новые ингибиторы гистондеацетилазы
ATE448833T1 (de) Haarbehandlungsmittel
ATE399012T1 (de) Carbaminsäurederivate enthaltend eine piperazin verknüpfung als hdac-inhibitoren
EA200000849A1 (ru) N-гидрокси-2-(алкил-, арил- или гетероарилсульфанил-, сульфинил- или сульфонил)-3-замещенный алкил-, арил- или гетероариламиды в качестве ингибиторов матричных металлопротеиназ
MA29500B1 (fr) Agents herbicides
EA200400026A1 (ru) Ингибиторы вич-протеазы, содержащие их композиции, их фармацевтические применения и вещества для их синтеза
UA87467C2 (xx) 4-((феноксіалкіл)тіо)феноксіоцтова кислота та її аналоги$4-((феноксиалкил)тио)феноксиуксусная кислота и ее аналоги
EP0677048A1 (fr) Inhibiteurs de proteases retrovirales contenant de la sulfone cyclique.
BR0213660A (pt) Composto, composição farmacêutica e método para tratar pacientes
TNSN00129A1 (fr) Inhibiteurs de l'aspartyle protease
EP1610678A4 (fr) Anticorps et compositions pharmaceutiques contenant ces derniers utiles pour inhiber l'activite de metalloproteines
EA200300334A1 (ru) Новая соль периндоприла и содержащие ее фармацевтические композиции
BR0315820A (pt) Inibidores de integrase de hiv, composições farmacêuticas e métodos para a sua utilização
CA2802696C (fr) Solution de soin pour lentilles de contact au peroxyde
FR2703249B1 (fr) Composition pharmaceutique ayant une activité analgésique contenant du naproxène.
Miller Patent status of histone deacetylase inhibitors